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Abstract
Background: Chagas disease is caused by the protozoan Trypanosoma cruzi and is characterized by heart failure
and sudden death. Identifying which factors are involved in evolution and treatment response is actually challenging.
Thus, the aim of this work was to determine the Th1/Th17 (IL-6, IL-2, TNF, IL-17 and IFN-γ) and Th2 (IL-4 and IL-10)
serum profile in Venezuelan Chagasic patients stratified according amiodarone treatment, hypertension and
arrhythmias.
Methods: Sera from 38 chagasic patients were analyzed to determine the level of cytokines by Multiplexed
Bead-Based Immunoassays. ANOVA test was applied to determine differences for each group. Additionally, a
Linear Discriminant Analysis (LDA) was applied to observe the accuracy of different cytokines to discriminate
between the groups.
Results: The levels of several cytokines were significantly higher in the high-risk of sudden death and
untreated group. LDA showed that IL-2, IFN-γ and IL-10 were the best cytokines for discriminating between
high-risk of sudden death and untreated patients versus low-risk of sudden death, treated and control groups.
Conclusions: High IL-2 levels seem to identify patients with high-risk of sudden death and seems adequate as
treatment efficacy marker. To our knowledge, this is the first report about the anti-inflammatory role of the amiodarone in
Chagas disease, suggesting an inmunomodulatory effect that may be exploited as coadjutant therapy in chronic Chagas
disease.
Background
Chagas disease is a neglected disease caused by the
intracellular protozoan Trypanosoma cruzi. Initially, it
was confined to Latin American countries, but has now
spread worldwide by immigration [1]. Besides, non-
traditional vectors have been recently involved in trans-
mission [2], raising the concern about the dissemination
in non-endemic countries.
Chagas disease is characterized by an acute phase,
generally asymptomatic or with mild unspecific symp-
toms, such as fever and hepatomegaly. Patients pro-
gress to chronic phase, being only a 30% symptomatic
during this stage. Chronic disease is characterized by
heart failure, arrhythmias and sudden death. Particu-
larly, sudden death represents 60% of mortality during
any stage. The victims often are younger than 58 years
and asymptomatic before the final episode [3], which
made challenging the finding of new prognosis markers
in order to identify patients with high-risk of heart failure
and sudden death. Besides, these hypothetical markers
would allow the evaluation of the response to the different
treatments applied to Chagasic patients.
Several risk stratification systems have been proposed
for Chagas disease. Some authors have postulated a clas-
sification that combines radiographic and echocardio-
graphic criteria with QRS morphology and appearance
of ventricular tachycardia [4, 5]. Other stratification
systems have focused their attention in the differential
cytokine response among patients with and without car-
diomyopathy. Some authors have reported that higher
* Correspondence: hrodrigu@ivic.gob.ve; hectorrod@gmail.com
†Equal contributors
1Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rodríguez-Angulo et al. BMC Infectious Diseases  (2017) 17:221 
DOI 10.1186/s12879-017-2324-x
IL-10 expression was associated with better cardiac
function, as determined by left ventricular ejection frac-
tion and left ventricular diastolic diameter values [6].
Besides, on the same grounds, other works have postu-
lated that reduced production of the cytokines IL-10 and
IL-17 in association with high levels of IFN-γ and TNF
correlates with the severity of the Chagas’ disease car-
diomyopathy, and the immunological imbalance ob-
served may be causally related with deficient suppressor
activity of regulatory T cells that controls myocardial in-
flammation [7]. In experimental animal models, IL-17
controls the resistance to acute T. cruzi infection
regulating the Th1 cells differentiation, cytokine and
chemokine production and control parasite-induced
myocarditis, regulating the influx of inflammatory cells
to the heart tissue [8]. However, our previous results
suggested that IL-17-producing T helper (Th)17 cells
may protect susceptible mice at low levels of infection,
but could, in association with IL-6, be pathogenic at high
parasite loads triggered by T. cruzi infection, whereas
regulation of the Th1 response by regulatory T cells play
a protective role in non-susceptible mice [9]. In the
same direction, this pro-inflammatory response needs to
be balanced in order to avoid tissue damage [10].
Despite these antecedents, there is little information
about the cytokine profile in patients under risk of sud-
den death. This information is important in order to
identify a valuable prognosis marker and to evaluate
the response to the antiarrhythmic and heart failure
therapy. These considerations should be taken into-
account because there are several reports about the role
of certain cardiovascular drugs in the modulation of
heart inflammation in Chagas disease. It has been
reported that captopril, an anti-hypertensive drug, was
able to ameliorate myocarditis in acute experimental
Chagas disease [11], although others have reported that
decreased the expression of the modulatory cytokine
IL-10 and development of the pro-inflammatory Th17
subset in human monocytes [12]. On the other hand,
amiodarone, an antiarrhythmic drug, has been reported
with anti-parasitic activity [13] and is able to improve
the clinical outcome in Chagasic patients [14]. Interest-
ingly, in the large >BENEFIT clinical trial, recently
released, the only patients showing some clinical bene-
fit were those taking amiodarone along with bendnida-
zole [15]. Nonetheless, reports about the possible role
of amiodarone in the regulation of inflammation in
Chagas disease are scarce. Thus, the aim of this work
was to determine the Th1/Th17/pro-inflammatory and
Th2/anti-inflammatory (serum profile in Venezuelan
Chagasic patients stratified according to blood pressure
status and Lown classifications and treated or not with
amiodarone to evaluate progression and the response
to treatment.
Methods
Human sera
Chagasic patients were diagnosed with two different sero-
logical tests (ELISA IgG and indirect haemagglutination),
according to WHO criteria. Patients aged 26 to 72 years
(mean 56.87), coming from North-West Venezuelan rural
and urban areas, and the presence of other infectious
disease (AIDS, TBC, Leishmaniosis, Toxoplasmosis), age
under 18 years and above 75 were an exclusion criteria.
Patients were recruited in a national specialized reference
centre for studying Chagasic arrhythmias in Caracas,
Venezuela. Following this diagnostic test results, patients
were grouped in healthy controls (n = 10, serology nega-
tive for Trypanosoma cruzi and the same criteria of exclu-
sion applied for Chagasic patients), cardiac chagasic
positive (n = 38). Patients were not paired by sex (27
female and 11 male), due to response of patients to the
service dating centre was not under the control of
researchers. Samples were taken by conventional vene-
puncture performed by trained personal, serum was ob-
tained by centrifugation and stored at −80 until use.
Cardiac Chagasic positive patients were characterized
following Lown criteria (Lown 0–2 n = 17, 3–5
n = 9) to evaluate their ectopic ventricular activity.
Data of patients with amiodarone treatment or with
cytokine data values out of distribution of the rest of
data were excluded (Additional file 1). According to
this classification, “0” stage represent patients without
ectopical activity and “5” to patients with R on T phenom-
ena (malignant ventricular arrhythmias). It should be
noted that is considered that patients in 0–2 classifications
are in low-risk (n = 17) and 3–5 classification are in high-
risk (n = 9) of sudden death (low- and high-risk SD hence-
forth). Data outliers were excluded in the same say stated
above. Finally, positive patients were divided regarding to
Amiodarone treatment. For this classification, only were
considered patients treated (n = 7, day by day at dosage of
200 mg daily five times a week) and untreated with a
similar Lown grade (n = 14). Clinical data was obtained
retrospectively and Amiodarone was prescribed based
in conventional clinical criteria (presence of symptoms
and reduced ejection fraction) independently of this
study and treatment classification was independent of
sudden death risk.
Cytokine quantitation
Fluorescent bead-based flow cytometry assays for 7 anti-
inflammatory and pro-inflammatory cytokines (CBA
Human Cytokine assays, BD Biosciences) were per-
formed in duplicate with human sera diluted 1:4, follow-
ing the manufacturer’s directions. Briefly, seven bead
populations with distinct fluorescence intensities coated
with capture antibodies specific for IL-2, IL-4, IL-6, IL-
10, TNF, IFN-γ, and IL-17A proteins were mixed
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together to form the bead array, which was resolved in
FL4 channel.Sample reading was performed in BIO
FACS Canto IITM Becton Dickinson (BD) cytometer
and analyzed with FCAP Array™ v1.0.1 for Windows.
After acquiring 30,000 events/microwell. Data was con-
verted to pg/ml using one phase association fit curves,
as is showed in Additional file 1.
Semi-quantitative analysis
The cytokine profile was first assessed by identifying low
and high cytokine producers, with slight modification
from as previously reported [16]. Briefly, threshold for
patients from all different groups was determined as the
value were 70% of sensitivity for each group in curves
ROC. These values were used as the cut-off mark to
label each patient as being a high or low cytokine produ-
cer. Then, in each group and for each cytokine, the re-
sults were expressed as the frequency of individuals with
a concentration of serum cytokine higher than the
threshold of group samples. The graphs were plotted
according to control frequencies in ascendant order.
Finally, graphs of each group in ascendant order were
overlaid to evidence cytokine signatures defined as those
cytokines with frequencies above the 50%. Additional
information about data distribution was added on
Additional file 1.
Multivariate statistical analysis
A multivariate ANOVA was performed in order to com-
pare individually the variables studied. A Linear Discrim-
inant Analysis (LDA) was applied to observe in which
proportion the levels of cytokines were actually able to
discriminate the study groups. LDA relates a variable
measured in nominal scale (dependent) with a group of
continuous variables, reducing dimensionality while pre-
serving as much of the class discriminatory information
as possible. The model assigns to each variable an axis,
from classical X, Y and Z to a transformed space. Space
reduction is based on correlation tests, where model
choose the less correlated variable (s), which contributes
in group discrimination. Thus, this method allows deter-
mining the most contributing variables. In addition, it al-
lows predicting the adscription of each individual to the
different groups studied with a certain probability [17].
Differences among classes are estimated by mean of
multivariate tests Wilks’ lambda, Pillai’s trace, Hotelling-
Lawley trace and Roy’s largest root that compute, in
general terms, the source of variance. Outliers were
determined by ROUT method and excluded of the ana-
lysis. Briefly, the program fits a theoretical non-linear
model with the data, were the outliers has little impact.
Thus, it uses a new outlier detection method, based on
the false discovery rate (FDR), to decide which points
are far enough from the prediction of the model to be
called outliers. FDR was fixed at value of 5%. Fisher
distances was used for determine distances between
calculated centroids.
Results
The levels of serum cytokines were determined in differ-
ent groups of patients including non-chagasic controls
and cardiac chagasic patients with different clinical sta-
tus per blood pressure, and Lown classifications and in
those presenting symptomatic treatment of arrhythmias
or not with amiodarone.
When stratifying the patients according to the Lown
classification, which is based on ventricular arrhythmias,
in high- and low-risk of sudden death (high- and low-
risk SD), a significant increment in all the cytokines
studied was observed in the high-risk SD group, but not
in the low-risk SD, respect to control group (Fig. 1). Dif-
ferent cytokine relative values of control and chagasic
patients stratified respect blood pressure in hypertensive
and normotensive are shown in Fig. 2. The ANOVA
statistical analysis indicated no significant differences be-
tween the groups. Most interestingly, patients treated
with amiodarone for arrhythmias presented a significant
decrease respect to the untreated ones in the relative
levels of most of the cytokines analyzed (Fig. 3). Add-
itionally, the percentage of high producer patients was
estimated as the value of patients above the threshold
determined by ROC analysis for each classification
(Additional file 1). IFN- and IL-17 showed the highest
percentages of high producers for Lown classification in
patients with high risk of sudden death and, interestingly
amiodarone treated group showed a global decrease of
high producer levels.
Linear discriminant analysis (LDA) was applied to find
a linear combination of variables, in this case cytokines
that characterize two or more classes of situations or
events, determining the variable (s) with the higher
discriminatory ability. In addition, the analysis could be
a predictive value for new individuals added to the dif-
ferent categories studied. In this case, the analysis was
performed to find a function that allows the separation
of the clinical groups where the individual differences
for each cytokine were unable to show significant
differences.
Striking differences in multivariate tests were observed
according to the Lown classification (Fig. 4a). Despite
some points generated in the transformed space are
slightly dispersed, the centroids were significantly sepa-
rated for all tests (Table 1). Fisher distances (Table 2)
shows that the differences are centered between high-
risk SD and low-risk SD groups, between high-risk SD
and control groups and between control and low-risk
SD. The function was able to predict retrospectively
77.78% members of high-risk SD, 70.59% for low-risk
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SD and 80% in the control group, with a global
power of prediction of 76.12% (Table 3). Notably,
LDA identified IL-2, IFN-ƴ and IL-10 as the most
contributing variables for the discrimination of the
Lown clinical stages (Table 4).
Multivariate tests on blood pressure stratified patients
showed significant differences for Roy’s greatest root and
Fisher distances tests (Tables 1 and 2). Although the
variation was lower in this classification (Fig. 4b), the
centroids of the groups of patients were too close to
each other (Table 1). Finally, the discriminant function
was not able to separate a posteriori with and high
accuracy Chagasic normotensive patients (45.33%) Cha-
gasic hypertensive (57.14%) and control (30%) (Table 3).
The plot for amiodarone treatment classification
shows the calculated centroids for each group (Fig. 4c).
In this case, LDA was able to differentiate differences
among treated group regarding to control and untreated
ones (Table 1 and 2). The confusion matrix (Table 3)
shows that the predictor function was able to separate a
posteriori treated (57%), untreated group (50%), and
control group (40%). Besides, Table 4 shows that LDA
determined IL-2 and IFN-ƴ as the most discriminatory
variable for treatment.
Discussion
One of the biggest challenges in Chagas disease’s re-
search is the searching for prognosis markers that help
to determine which patients are in potential risk to de-
velop the most devastating pathological consequences of
the disease. On the other hand, comprehension of the
pathophysiological processes involved in such evolution
can lead to the design of a better rational therapy for
improving the outcome of the patients during the
chronic phase.
With the appearance of more sensitive techniques for
detecting parasite antigens or DNA antigens in chronic
lesions [18] it was thought that the parasite antigens
persistence may play a role in the persistence of inflam-
mation and the progression of pathology [19]. Besides,
some studies associate Beznidazole treatment, a parasiti-
cide drug, with better outcome in chronic Chagasic pa-
tients [20]. However, the recent report on the BENEFIT
study that involved 2854 Chagasic patients from differ-
ent geographic regions, failed to demonstrate any signifi-
cant association between Beznidazole treatment and
better clinical outcome [15], bringing back the concern
about identifying factors involved in disease progression.
Interestingly, in this study, the only group that appeared
Fig. 1 Cytokine levels for patients stratified following Lown criteria. Graphs show the mean +/− SEM values of values (expressed in pg/ml) for
IL-17, IFN-γ, TNF, IL6, IL-2, IL-10 and IL-4 to Lown scoring classification (showed as risk of sudden death and non-arrhythmic uninfected control in
bars). Significance both any group is marked with *, ** and *** in function of p values (*: >0.05 < 0.02; **: >0.02 < 0.01 and ***: >0.01). N value
was 26 for Lown classification (17 low-risk vs. 9 high-risk). Male/female ratio were 4/5 for high-risk group and 5/12 for low-risk group and age
mean were 56.222+/− 5.191 (high-risk group) and 53.588 +/− 11.138 (low-risk group). For additional information, the reader is referred to M&M
section and Additional file 1
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to benefit from therapy was the amiodarone treated
group, but without any apparent effect on parasitic load
[15, 21]. In this direction, we decided to explore the
cytokine profile of Chagasic patients stratified by clinical
status for sudden death risk (Lown classification), blood
pressure status (hypertensive versus normotensive) and
Amiodarone treatment, to discriminate the concomitant
conditions that can influence the patient’s inflammatory
status and, consequently, the outcome of the disease.
Interestingly, high-risk SD patients showed a significant
overall increase of cytokine levels associated with in-
creased high-producer frequencies. All multivariate tests
and Fisher distances were able to find differences among
centroids, especially between high- and low-risk SD
groups. LDA predicts a very high percentage of high-
(77.78%) and low-risk SD (70.59%), which strongly sug-
gests association between inflammation and arrhythmia
and postulate cytokine profiles as a plausible predictor of
arrhythmias in Chagasic patients. Malignant arrhythmias,
often asymptomatic, are the leading cause of death in Cha-
gasic patients [22] and, in the best of our knowledge; this
is the first report that associates cytokine profiles with ar-
rhythmias in Chagas disease and it could open a field for
better understanding the pathophysiology of this disease.
The role of inflammation in the genesis of arrhythmias
is still and elusive issue in pathophysiology of sudden
death. Infliximab, an TNF blocker, could reduce the
frequency of mice afflicted by arrhythmias and second
degree atrioventricular blocks in an experimental model
of chronic Chagas disease [23]. Gene expression of pro-
inflammatory factors associated to inflammatory re-
sponse (IFN-γ, transcription factor T-bet, GATA-3;
FoxP3 and CTLA-4; IL-17 and IL-18) were upregulated
in heart samples of chronic Chagasic patients [24] and
its inflammatory environment has been reported as in-
ductor of gene expression related with heart failure [25]
and gap junction dysfunction during Chagas disease
[26], possibly explaining this fact the electrical distur-
bances observed in patients. Interestingly and closely re-
lated with our results, IL-2 was able to induce in vitro
the expression of SCN3B and sodium current density
[27], increasing of atrial action potential duration [28]
and IL-2 has been linked to prognosis for atrial fibrilla-
tion in patients [29]. Additionally, Cx43 gene expression,
a key protein of gap junctions tightly related with action
potential spreading onto the heart, has been reported as
impaired in Chagasic cardiomyopathy, reinforcing the
possible association between inflammation and altered
electrical function in Chagasic patients [30] and its fact
possibly explains the positive effect of amiodarone treat-
ment during Chagas disease [31]. Taken together, our
results suggest that the cytokines, specially the pro-
Fig. 2 Cytokine levels for patients classified according Blood pressure status. Graphs show the mean +/− SEM values of values (expressed in pg/ml) for
IL-17, IFN-γ, TNF, IL6, IL-2, IL-10 and IL-4 to Blood pressure classification (showed as normotensive, hypertensive and normotensive non-chagasic controls
in bars). Significance both any group is marked with **, ** and *** in function of p values (*: >0.05 < 0.02; **: >0.02 < 0.01 and ***: >0.01). N value was
38 for blood pressure classification (14 hypertensive vs. 24 normotensive). Male/female ratio was 4/10 for hypertensive group and 7/17 for normotensive
group and age mean were 57.286 +/− 6.170 (hypertensive group) and 55.583 +/− 10.579 (normotensive group). For additional information, the reader
is referred to M&M section and Additional file 1
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inflammatory ones, play a key role in arrhythmias and
sudden death and may be explored in patients as a
potential risk factor of malignant arrhythmias.
On the other hand, the serum cytokine profile showed
in the present work cab be related with previous report
of cardiac inflammatory milieu. TNF, IL-2, IL-10 and
IFN-ƴ has been reported as locally produced by the in-
flammatory infiltrate in samples of human Chagasic
hearts [32, 33], suggesting that may play a role on the
differential susceptibility to chronic Chagas disease de-
velopment. Other works have described the presence of
IL-2, IL-4 and IL-6-producing mononuclear cells in
Fig. 4 LDA analysis box plot for Lown (a), Blood pressure (b) and treatment classification (c). Axes represent the discriminant functions (F1 and
F2) resulting from redundancies analysis and the variation conserved for each one onto the transformed space is showed in brackets for each
discriminant function. Centroids (filled black circles, group pointed with continuous line) and confidence ellipses (unfilled black ellipses) are
showed for each group. Finally, each small coloured circle represents individual data for each classification, as can be appreciated on the top of
each axis
Fig. 3 Cytokine levels for patients classified according amiodarone treatment. Graphs show the mean +/− SEM values of values (expressed in pg/ml)
for IL-17, IFN-γ, TNF, IL6, IL-2, IL-10 and IL-4 to amiodarone treatment classification (showed as treated, untreated and untreated non-chagasic controls
in bars). Significance both any group is marked with **, ** and *** in function of p values (*: >0.05 < 0.02; **: >0.02 < 0.01 and ***: >0.01). N value was
21 for item treatment classification (7 treated vs 14 untreated). Male/female ratio was 2/5 for treated group and 4/10 for untreated group and age
mean were 61.143 +/− 6.440 (treated group) and 57.786 +/− 4.995 (untreated group). For additional information, the reader is referred to M&M section
and Additional file 1
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Chagas heart tissue, associated with T. cruzi antigen
presence [34]. In addition, recent publications have
reported data showing that Chagasic patients with
ventricular dysfunction had increased plasma levels of
IL-10, IFN- , IL-6, TNF and IL1-β. Based on that, we
may suggest that exist association among Th1/Th2/Th17
serum profile and in situ cardiac inflammation, reinfor-
cing the profile proposed in this work as good marker of
cardiac disease.
Normotensive Chagasic patients showed no significant
differences in relative levels with respect to controls.
Additionally, LDA analysis only found differences among
centroids from control and normotensive group and has
poor results for hypertensive Chagasic (57.14%) and con-
trol patients (30%) suggesting that hypertension was not
associated with an inflammatory pattern in Chagasic
patients. However, it is worth mentioning that anti-
hypertensive drug treatment, although it was not a vari-
able considered in this study, also decreased the levels of
high producers in hypertensive patients (Additional file 1)
[35]. Thus, it is probable that most of them were under
anti-hypertensive treatment. Several drugs used for hyper-
tension have been associated with anti-inflammatory
properties [36] although in Chagasic patients the available
data is contradictory [12]. Further studies are needed to
resolve this issue.
On the other hand, LDA was able to identify IL-2 as
the best discriminator variable, both in treated and un-
treated arrhythmic patients. Although this data does not
allow itself to state that the increasing nor decreasing of
IL-2 levels are associated to any outcome, high IL-2
serum levels have been reported as an atrial fibrillation
predictor [29, 37] and low levels have been associated
with therapeutic success of amiodarone treatment in
atrial fibrillation [38]. Further studies are necessary for
elucidating the molecular mechanisms associated to the
heart microenvironment during chronic Chagas disease.
Finally, Amiodarone treated patients, paired with un-
treated Chagasic patients with the same arrhythmia
Table 2 Fisher distances among LDA calculated centroids
p-values for Fisher distances: Blood pressure
Control Hypertensive Normotensive
Control 1 0.2535 0.0464
Hypertensive 0.2535 1 0.1283
Normotensive 0.0464* 0.1283 1
p-values for Fisher distances: Lown
Control High-risk SD Low-risk SD
Control 1 0.0002* 0.0292*
High-risk SD 0.0002* 1 < 0.0001*
Low-risk SD 0.0292* < 0.0001* 1
p-values for Fisher distances: Treatment
Control Treated Untreated
Control 1 0.0467* 0.0731
Treated 0.0467* 1 0.0050*
Untreated 0.0731 0.0050* 1
Fisher Distances Each subsection shows p values (significance >0.05, (*) bold when
appear) from calculated Fisher distances among LDA centroids for sub-groups of
the clinical classification used in this study. The p value corresponds to the
intersection between column and rows variables
Table 1 LDA multivariate significance tests
Wilks’ Lambda test Pili’s trace Hotelling-Lawley trace Roy’s greatest root
Blood pressure 0.0587 0.0543 0.0673 0.0379*
Lown < 0.0001* 0.0001* < 0.0001* < 0.0001*
Treatment 0.0054* 0.0052* 0.0075* 0.0040*
Multivariate tests from LDA that show comparison of vector means. Significance (p values >0.05) implies that at least one of the means vector is different from
another. Significant values (*) are showed in bold
Table 3 LDA confusion matrix
Confusion matrix for the estimation sample: Blood pressure
from \ to Control Hypertensive Normotensive Total %
correct
Control 5 8 3 16 30.00%
Hypertensive
2 9 5 16 57.14%
Normotensive
2 7 7 16 45.83%
Total 9 24 15 48 44.33%
Confusion matrix for the estimation sample: Lown
from \ to Control High-risk SD Low-risk SD Total %
correct
Control 10 0 2 12 80.00%
High-risk SD 3 9 0 12 77.78%
Low-risk SD 3 1 8 12 70.59%
Total 15 10 11 36 76.12%
Confusion matrix for the estimation sample: Amiodarone treatment
from \ to Control Treated Untreated Total %
correct
Control 4.13 0.00 6.20 10.33 40.00
Treated 4.43 5.90 0.00 10.33 57.00
Untreated 2.95 2.21 5.17 10.33 50.00
Total 11.51 8.12 11.37 31.00 49
LDA calculates membership probabilities an assign a group a posteriori in
function of the higher probability obtained. Table shows the percentage of
correspondence of the assignments compared with a priori
known membership
Rodríguez-Angulo et al. BMC Infectious Diseases  (2017) 17:221 Page 7 of 10
classification, showed a decrease of cytokine levels and to
levels like control group. It is interesting and could sup-
port the better prognosis observed in combination with
beznidazol (in comparison with antiparasitic drug alone)
reported by BENEFIT trial (Fig. 1 and Additional file 1).
In a recent study, it was reported that amiodarone was
able to inhibit in a dose dependent way the production of
cytokines, IL-2, IL-4, TNF, and IFN-γ in activated human
T cells through NFκβ and activate protein-1 modulation
[39] and suppress the expression of IL-2 receptor-alpha
(CD25) and CD69, cell surface markers of activated T cells
[39]. Amiodarone has been reported to reduce poly-
morphonuclear leukocyte infiltration in the paw tissue
and paw edema in a dose dependent way [40]. Neutrophil
differentiation has been associated with increased IL-17
[41], suggesting that Amiodarone treatment may be asso-
ciated with lower levels of IL-17 indicating lower Th17
lymphocyte response. Along those lines, it has recently
been reported that Amiodarone treatment was able to
improve heart failure prognosis in patients by decreasing
IL-17 and IL-6 levels [42] which suggest that a pro-
inflammatory state could be related with arrhythmias/
heart failure and being benefited with amiodarone treat-
ment. LDA was able to find significant distances among
centroids from treated and untreated patients, but fails to
predict the patients belonging to treated and untreated
groups.
Conclusion
Overall, a limitation of this study was the relatively low
number for some groups of patients, especially those
related with high scoring of arrhythmias. In the case of
arrhythmias, it should be kept in mind the fact that it is
a non-symptomatic alteration which generates a high
sub-register for patients for high sudden death risk.
Additionally, the diagnosis of arrhythmias often requires
a very specialized medical evaluation and it is not always
available for low incoming patients that are generally
those mainly affected by Chagas disease. The pattern of
patient affluence and the scarcity of centres specialized
in arrhythmia diagnosis and treatment also limited the
pairing of patients by sex and age. Although we did not
observe significant differences between cytokine values
discriminated by sex, nor correlation with age, it is neces-
sary a larger scale study for elucidate the influence of these
variables in cytokine levels. Despite those, the present
work gives valuable insights on the relationship between
inflammation and arrhythmias in Chagas disease. It also
provides evidences about the role of Amiodarone as im-
munomodulatory agent in Chagasic patients, suggesting
that it can help to improve the disease outcome, as
recently demonstrated [15], through the mechanism
described here. Last but not least, our results could help
to propose a model of prognosis for evolution that is able
to discriminate a characteristic profile for arrhythmic
patients.
Additional file
Additional file 1: Figure S1. One phase association fit curves for
pattern curve data. Axes represent association between mean fluorescence
(MFI) values obtained for different know cytokine with results expressed in
pg/ml (y axis). Y=Y0 + (Plateau-Y0)*(1-exp.(-K*x)) equation was used for
calculating cytokine concentration for patient samples. Figure S2. High
producer frequencies for Lown stratified Chagasic patients. Bar graph shows
the percentage of high producers for the different cytokines studied for
Lown clinical scoring. Control high producer’s percentages is showed as
dotted line and Chagasic frequencies (high & low SD risk) as bars. Threshold
to determining high producers was calculated on ROC curve values for
patients included in this group. Figure S3. High producer frequencies for
blood pressure stratified Chagasic patients. Bar graph shows the percentage
of high producers for the different cytokines studied for blood pressure
clinical scoring. Control high producer’s percentages is showed as dotted
line and Chagasic frequencies (normotensive & hypertensive) as bars.
Threshold to determining high producers was calculated on ROC curve
values for patients included in this group. Figure S3. High producer
frequencies for amiodarone treatment stratified Chagasic patients. Bar graph
shows the percentage of high producers for the different cytokines studied
for blood pressure clinical scoring. Control high producer’s percentages is
showed as dotted line and Chagasic frequencies (untreated & treated) as
bars. Threshold to determining high producers was calculated on ROC
curve values for patients included in this group. (XLSX 980 kb)
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